Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buccal buspirone as adjunctive therapy in GERD patients
IRCT20121021011192N7Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of buspirone in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Improvement of clinical symptoms of GERD disease. Started Oct 2018; status: completed.
02
Drugs
buspirone
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on IRCT20121021011192N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20121021011192N7.